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Introduction
　Anxiety disorders are a group of disorders marked by 
symptoms of uneasiness. Generalized anxiety disorder, so-
cial phobia, panic disorder, and acute stress disorder are in-
cluded in the anxiety disorder category in the DSM-Ⅳ-TR. 
The prevalence of anxiety disorders is substantial in the 
general population and their functional impact is signifi-
cant. However, the causes of anxiety disorders have not 
been scientifically explained.
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Background: Anxiety disorders are mental disorders that cause somatic symptoms for which patients may seek care from gen-
eral medicine departments. We focused on anxiety disorders in middle-aged patients and examined the effect of a psychothera-
peutic intervention.
Materials and Methods: The participants were 14 middle-aged patients diagnosed with an anxiety disorder. Patients received 
pretreatment assessments and were randomly assigned to a pharmacotherapy group (n = 8) or a pharmacotherapy and psycho-
therapy group (n = 6). The duration of the study was three months. Pre-and post-treatment, the Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36), State-Trait Anxiety Inventory (STAI), and a visual analog scale (VAS) were administered. In 
the pharmacotherapy and psychotherapy group, salivary cortisol was collected pre- and post-psychotherapy at the first and final 
psychotherapy sessions. 
Result: Four patients in the pharmacotherapy group withdrew from the study. There were no significant differences in the total 
scores of the SF-36 or STAI between groups. Improvement was seen in the pharmacotherapy and psychotherapy group pre- and 
post- treatment. SF-36 subscales of bodily pain (p = 0.02) and mental health (p = 0.04)  were significantly higher than post-
treatment. The state anxiety score on the STAI improved post-treatment (p = 0.03). On the VAS, the pharmacotherapy and psy-
chotherapy group’s symptoms were significantly improved (p = 0.02). 
Conclusion: This suggests that psychotherapy for middle-aged individuals contributes to the improvement of anxiety states and 
HRQoL in general medicine departments. It promotes the recognition of curative effects and prevents doctor shopping.  
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　Anxiety disorders are mental disorders that cause somat-
ic symptoms for which patients may seek and receive treat-
ment through a general medicine department1,2. If medical 
care does not provide the appropriate diagnosis and treat-
ment, the patient may not understand the illness and be dis-
satisfied with the treatment. This may lead to the patient 
visiting various hospitals and doctors until an explanation 
or appropriate treatment is found3,4. Thus, the identification 
of anxiety disorders is required in general medicine depart-
ments 1,5,6.
　In recent years, the physical factors of anxiety disorders, 
including brain dysfunction theory, have become influen-
tial, although social factors and psychological factors must 
also be considered. In addition in treatment effect studies, 
a variety of approaches, such as pharmacotherapy and 
cognitive behavioral therapy, have been attempted and 
studied7-9.
　The examination of age group studies on anxiety disor-
ders have focused on the elderly10-12, long-term outcomes, 
and the need for early treatment13. There are relatively few 
studies except for the elderly. However, in middle age, indi-
viduals experience physical decline, children moving out of 
the family home, caring for aging parents, and changes in 
the workplace such as early retirement. Such social prob-
lems may lead to financial and psychological problems; 
thus, it may be difficult to feel settled14. Therefore, in this 
study, we decided to examine the effects of psychotherapy 
in middle age on such a psychosocial background.
　In the evaluation of psychotherapy effects dropout rates 
are an issue15-17. Reasons of dropout have been examined 
from perspectives of disease differences, patient character-
istics, and feelings of satisfaction. In psychotherapy, the 
clinical psychologist talks with a patient in a private room at 
a scheduled time. The topic focuses on the patient experi-
ence. We considered that stress in talking with psycholo-
gists might cause burden and be one of the reasons for drop-
outs. Therefore, we collected salivary cortisol to measure 
the burden of the psychotherapy objectively. Salivary corti-
sol attracts attention as one of the physiological evaluation 
methods of stress. Cortisol is the hormone that is important 
in assessing about psychological and physical health condi-
tions18. It is shown that salivary cortisol rises with stress in 
the laboratory research19. We examined the burden of psy-
chotherapy from a change in salivary cortisol. 
Study Participants
　In this study, ages 40–60 were defined as middle age. 
Fourteen patients who had a diagnosis of an anxiety disor-
der in a general medicine practice were recruited through 
general physician referral. Diagnostic assessments included 
the administration of the Structured Diagnostic Interview 
for DSM-IV. The selection criteria included the DSM-IV 
diagnoses of anxiety disorders, middle age, willingness to 
participate in the study, and willingness to consider psycho-
therapy. We excluded individuals receiving medical 
treatment for anxiety disorders at another hospital. Partici-
pants were given pretreatment assessments and randomly 
assigned to a pharmacotherapy group (n = 8) or a pharmaco-
therapy and psychotherapy group (n = 6). The pharmaco-
therapy group received a periodic medical examination and 
medicine prescription by a general physician. The pharma-
cotherapy and psychotherapy group received psychotherapy 
with the clinical psychologist in addition to medical exami-
nation and medicine prescription by a general physician. 
The psychologist was a qualified clinical psychologist with 
eight years of experience. The duration of the study was 
three months (Figure 1). 
　At the beginning of the psychotherapy, the clinical psy-
chologist explained the purpose and method of psychother-
apy and began psychotherapy with patient consent. Psycho-
therapy lasted about 60 minutes. We completed the medical 
examination and the psychotherapy in another room. The 
patient sat on a chair with a backrest and talked with a psy-
chologist across a table. The psychotherapy schedule was 
established by the patientsʼ circumstances and schedules. 
The patient and the psychologist talked and scheduled ap-
pointments for the next time as the psychotherapy session 
MATERIALS AND METHODS
 
      
 Pre-treatment evaluation      Structured Clinical Interview for DSM-IV 
                  SF-36・STAI 
                  Random assignment   
   Pharmacotherapy and Psychotherapy     Pharmacotherapy 
     group                                 group         
First session of psychotherapy 
Saliva extraction of pre- and post- psychotherapy 
 
Final session of psychotherapy 
Saliva extraction of pre- and post- psychotherapy 
 
  Post-treatment evaluation          SF-36・STAI・VAS 
 (three months later)              
        Figure 1 
Figure 1. Progress and evaluation of research 
Figure 1. Progress and evaluation of research
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ended. The schedule began at the rate of once or twice a 
week and the interval gradually increased. We conducted an 
average of six psychotherapy sessions during the study.
 
Measures
　Outcome measures included the State-Trait Anxiety In-
ventory (STAI) for Japan (Form X), the Medical Outcomes 
Study Short Form-36 (SF-36)20,21, a visual analog scale 
(VAS), and a salivary cortisol measure.
Questionnaires 
　Anxiety was measured with the Japanese version of the 
State–Trait Anxiety Inventory (Form X). The State–Trait 
Anxiety Inventory was developed by Spielberger, et al.22 to 
determine individualsʼ separate state and trait anxiety levels 
and has been standardized for Japan. The State–Trait Anxi-
ety Inventory consists of a State Anxiety Scale (STAI-S) 
and a Trait Anxiety Scale (STAI-T). The STAI is a self-eval-
uation scale containing 40 expressions. This questionnaire 
was completed pre- and post-treatment.
　Health-related quality of life (HRQoL) was measured 
with the SF-36 (Japanese version 2, Acute; iHope Interna-
tional, Japan)23 to determine the range of functional impair-
ment of anxiety disorders in primary care patients24,25. The 
questionnaire consists of 36 items in eight dimensions of 
functioning. Physical functioning, physical role, bodily 
pain, general health, vitality, social functioning, emotional 
role, and mental health concepts of the SF-36 were measured 
on a five point Likert scale with varying answers. This ques-
tionnaire was completed pre- and post-treatment. 
Visual analog scale
 
　Patient treatment achievement was measured with a visual 
analog scale. Pre-treatment, we confirmed the achievement 
level the participant expected from the treatment. Post-treat-
ment, all patients were asked to plot their treatment achieve-
ment on a 10-cm horizontal line. Marks were made on a 10-cm 
line with 0 =  pre-treatment at one end and 10 =  full treatment 
achievement expected by the participant at the other end.
Psychoneuroendocrine response
　We also measured participantsʼ salivary cortisol (a hor-
mone) and examined the stress reaction to psychotherapy. 
Salivary cortisol was chosen because other measures, such 
as blood draws, may cause pain and uneasiness. Salivary 
cortisol is easily collected and is not a burden for partici-
pants18. The pharmacotherapy and psychotherapy group 
members measured salivary cortisol pre- and post-psycho-
therapy at the first and final psychotherapy sessions. To ex-
clude the measurement influence, the pre-psychotherapy 
measurements were collected after a ten-minute rest and the 
post-psychotherapy measurements were collected just after 
psychotherapy. They were collected at the same time in the 
first and final psychotherapy sessions. Salivary cortisol was 
collected using Salivette®. This is a container with cotton 
that doubled in size in a spitz pipe. The subject removes the 
cotton from the container and allows saliva to soak thor-
oughly. After collecting, the cotton was placed in a con-
tainer, sealed, and cryopreserved.
Semi-Structured interview
　A semi-structured interview was conducted at pre-treat-
ment for all patients. The interview was completed with a 
questionnaire. Contents included a clinical history, family 
structure, life behavioral patterns, and work experience.
Ethical Considerations
　The study protocol was approved by the Medical Ethics 
Committee of Nagasaki University. Written informed con-
sent was obtained from each subject in accordance with the 
Helsinki Declaration. 
Statistical Analysis
　Intention-to-treat analyses were performed. The Mann-
Whitney U test and Wilcoxon signed rank test were used to 
find pre- and post-treatment differences between the groups. 
Statistical significance was set at p < 0.05. All statistical 
analyses were performed with EZR (Saitama Medical Cen-
ter, Jichi Medical University, Saitama, Japan), which is a 
graphical user interface for R (The R Foundation for Statis-
tical Computing, Vienna, Austria )26. More precisely, it is a 
modified version of R commander designed to add statisti-
cal functions frequently used in biostatistics.
RESULTS
Participant characteristics
　Among fourteen participants, four participants of the 
pharmacotherapy group withdrew from the study. One pa-
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tient transferred to the psychiatry department and the other 
patient canceled study entry. We did not understand the rea-
sons for the other two people. One had a history of six con-
sultations and one medication experience. The other one 
had a history of one consultation without taking medicine. 
We hypothesized that they hoped for treatment unlike other 
hospitals or did not want to take medicine. 
　Demographic and clinical data for the participants are 
presented in Table 1. There were seven women and seven 
men ranging in age from 41 to 58 years. The period of anxi-
ety symptoms, the number of hospitals patient had consult-
ed for anxiety symptoms, and the medication history for 
anxiety disorders did not differ between groups. For phar-
macotherapy, an antianxiety medication, a sleep medica-
tion, and an antidepressant were prescribed. We performed 
an equivalent conversion calculation to compare the pre-
scription contents. We used diazepam as the reference anti-
anxiety and sleeping drug, and imipramine as the reference 
antidepressant (Table 2). There were no differences in the 
prescription contents of antidepressants, antianxiety medi-
cations, or sleeping medications for pharmacotherapy be-
tween groups. 
SF-36 pre- and post-treatment in the pharmacotherapy 
and psychotherapy group
　The scores of eight people in the pharmacotherapy group 
and six people in the pharmacotherapy and psychotherapy 
group were used for analysis. The median scores are includ-
ed in Table 3. The groups did not differ at pre-treatment on 
any demographic or clinical variables. In the pharmacother-
apy and psychotherapy group, the total SF-36 score im-
proved from pre- to post-treatment. There was a significant 
difference in the reports of bodily pain scores (p = 0.02) and 
mental health scores (p = 0.04).
　Table 1. Demographic and clinical participant characteristics (N = 14)
Pharmacotherapy
 group (N = 8)
n or M (range)
Pharmacotherapy and 
psychotherapy group (N = 6)
n or M (range)





　　Employed full-time 4 3







Existence of living together
　　Family 5 6
　　Unclear 3
Mean time of symptom duration by the report of the patient 208 days (7–730) 203 days (1–730)
The number of hospitals which patient had consulted for anxiety 
symptoms
2.25 (0–6) 1.8 (0–4)
Medication taken for the anxiety disorder
　　Yes 2 1
　　No 6 5
Dropout from study 4
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STAI scores pre- and post-treatment of the pharmaco-
therapy and psychotherapy group
　There was no significant difference between the pharma-
cotherapy group and the pharmacotherapy and psychother-
apy group on the STAI. As shown in Table 3, the state anxi-
ety score of the pharmacotherapy and psychotherapy group 
improved between pre- and post-treatment (p = 0.03).
VAS comparison of the pharmacotherapy group and the 
pharmacotherapy and psychotherapy group
　The VAS scores were significantly different between the 
pharmacotherapy group and the pharmacotherapy and psy-
chotherapy group (Table 3). The pharmacotherapy and psy-
chotherapy group reported higher degrees of treatment 
achievement than the pharmacotherapy group (p = 0.02).
Salivary cortisol pre- and post- psychotherapy
　In the pharmacotherapy and psychotherapy group, there 
was no difference in pre- and post-psychotherapy salivary 
cortisol between first and final psychotherapy sessions. We 
compared the salivary cortisol of post-psychotherapy in the 
first psychotherapy session and final psychotherapy session. 
There was a tendency for salivary cortisol to decrease (p = 
0.06; Table 4). 
Table 2. The medicines that were prescribed for both groups
Case
Dose that is
 equivalent to 
5 mg diazepam
(mg/day)






Case 1 Etizolam 1 mg
3.3 (3.1–5.63) 37.5 (37.5–45)
Case 2 Zolpidem Tartrate 10 mg
Bromazepam 2 mg
Milnacipran Hydrochloride 30 mg
Case 3 Paroxetine Hydrochloride 20 mg 
Etizolam 0.5 mg
Case 4 Fludiazepam 0.5 mg
Case 5 Etizolam 1 mg
Sertraline Hydrochloride 25 mg
Case 6 Zolpidem Tartrate 5 mg
Case 7 Etizolam 1 mg
Paroxetine Hydrochloride 10 mg
Case 8 Paroxetine Hydrochloride 10 mg






Case 9 Hangekobokuto 7.5 g
6.67 (6.17–8.34) 75 (37.5–75)
Case 10 Paroxetine Hydrochloride 20 mg
Case 11 Paroxetine Hydrochloride 10 mg
Zolpidem Tartrate 10 mg
Etizolam 0.5 mg
Case 12 Diazepam 4 mg, Etizolam 0.5 mg
Case 13 Sertraline Hydrochloride 50 mg
Case 14 Clotiazepam 20 mg
Median (interquartile range)
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Pharmacotherapy and psychotherapy 
group
Pre- Post- Pre- Post-
40 50 42.5 55 
SF-36 Mental health
(30–50)  (37.5–61.25) (25–48.75) (51.25–70)*
75 50 45.85 66.65 
Emotional role
(47.93–87.48) (43.75–50) (29.18–56.23) (45.85–93.75)
30 40 35 45 
General health
(25–41.25) (33.75–49.25) (18.75–52.75) (45–52)
92.5 87.5 77.5 87.5 
Physical functioning
(87.5–100) (68.75–96.25) (66.25–88.75) (77.5–93.75)
62.55 62.5 46.9 53.15 
Physical role
(48.45–75) (48.45–75) (20.33–59.38) (45.35–70.33)
47 81 46.5 57
Bodily pain
(19.5–57) (54.25–100) (26.75–58.75) (43.75–69.5)*
56.25 50 56.25 62.5 
Social functioning
(37.5–75) (43.75–53.13) (40.63–71.88) (62.5–71.88)
21.9 40.65 40.65 46.9 
Vitality
(12.5–29.7)  (15.68–67.2) (28.13–48.45) (43.8–64.1)
54 56 61 48
STAI Trait
(51.5–57) (49.25–57.5)  (53–66) (40–59)
57 53 56 47
State





SF-36: Medical Outcomes Short Form-36; STAI: State-Trait Anxiety Inventory-JYZ.
*P < 0.05 is considered statistically significant comparisons of scores pre- and post-treatment in the psychotherapy group.
Table 4. Salivary cortisol concentration of pre- and post-psychotherapy at the first and final psychotherapy sessions
First session Final session
Pre-psychotherapy Post-psychotherapy Pre-psychotherapy Post-psychotherapy
μg /dl 0.18 (0.16–0.27) 0.25 (0.23–0.3) 0.21 (0.16–0.26) 0.155 (0.14–0.24)
Median (interquartile range)
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　In this study, we investigated the effect of psychotherapy 
interventions for anxiety disorders in middle-aged patients 
who visited a general medicine department.
　We compared the HRQoL subscale scores on the SF-36. 
Vitality scores, mental health scores, and bodily pain scores 
improved pre- to post-treatment in the pharmacotherapy 
and psychotherapy group. Anxiety sensitivity is an inde-
pendent predictor of bodily pain scores and social function-
ing scores on the SF-3627. The association between anxiety 
sensitivity and pain is of interest. Anxiety sensitivity pre-
dicts bodily pain score since individuals with high anxiety 
sensitivity usually have beliefs about the harmfulness of 
certain bodily sensations28. 
　In the pharmacotherapy and psychotherapy group, the 
state anxiety score on the STAI significantly improved. The 
VAS score showed that the pharmacotherapy and psycho-
therapy group felt closer to expected treatment achievement 
than the pharmacotherapy group. This suggests that psy-
chotherapy contributed to the improvement of anxiety 
states. 
　Psychotherapy includes listening to patientsʼ thoughts 
and feelings. We addressed not only the anxiety symptoms 
but also patient action and changes in disease conscious-
ness. There was an opportunity to “restructure” the patientsʼ 
past experiences. Psychotherapy decreases the influence of 
vague unease and offers the opportunity to improve the 
state of uneasiness. Of course, pharmacotherapy also in-
cludes listening to patientsʼ thoughts and feelings. However, 
pharmacotherapy required shorter consultation hours for 
one patient than psychotherapy. In a medical examina-
tion, the progress of anxiety symptoms is evaluated. Evalu-
ation of the benefits and the side effects of medication were 
important in physician examinations. 
　Anxiety disorders are often accompanied by anticipatory 
anxiety. Even if anxiety symptoms were improved by phar-
macotherapy, a patient with an anxiety disorder may have 
continuing anticipatory uneasiness29. Patient with anxiety 
disorders tend to be sensitive to symptoms and avoid events 
that cause uneasiness in their daily life. Therefore, we can 
expect a decrease in action restrictions by talking about an-
ticipation uneasiness by psychotherapy.
　Studies on psychotherapy for anxiety disorders have been 
reported recently8,24,30. However, psychotherapy may not 
only affect but also burden a patient. The patient may face 
the problem at some other time. 
　In this study, we collected salivary cortisol to examine 
objectively the burden that psychotherapy itself caused a pa-
tient. There was a tendency for stress, as measured by sali-
vary cortisol, to decrease over time in the pharmacotherapy 
and psychotherapy group. Before psychotherapy, the patient 
may have found it difficult to talk with a psychologist in the 
first psychotherapy session and been uncertain about the 
procedures. Such anxiety may have caused stress for the pa-
tient. However, the tendency for stress seen in the cortisol 
values decreased post-psychotherapy of the final session. 
This suggests that any stress associated with psychotherapy 
diminishes over time.
　This psychotherapy intervention study was completed in 
general medicine31,32. In mental health care, physician-pa-
tient alliance and communication are associated with more 
favorable patient adherence33. In the general medicine de-
partment, the patient has already consulted multiple hospi-
tals including psychiatry, refuses consultation and psychiat-
ric medication, and may feel a limit to pharmacotherapy. In 
this study, the curative effect may have increased because a 
general physician and a psychologist treated cooperatively. 
The combination of pharmacotherapy and psychotherapy 
can provide appropriate treatment for the patient. It pro-
motes the recognition of curative effects. If a patient can 
recognize a curative effect, doctor shopping may be pre-
vented34.
　The limitations of this study included the small number 
of cases and the treatment duration. We intended to study 
middle age. However, we were not able to clarify whether 
the result was peculiar to middle age. We think that the 
background of the uneasiness of each generation is differ-
ent. Based on this result, we will adopt a qualitative psycho-
therapy study as the next step to clarify characteristic fac-
tors and curative effects for middle age.
DISCUSSION
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